Your browser doesn't support javascript.
loading
Longitudinal Feasibility of the Montreal Cognitive Assessment (MoCA) in Non-Demented ALS Patients.
Aiello, Edoardo Nicolò; Solca, Federica; Torre, Silvia; Colombo, Eleonora; Maranzano, Alessio; De Lorenzo, Alberto; Patisso, Valerio; Treddenti, Mauro; Curti, Beatrice; Morelli, Claudia; Doretti, Alberto; Verde, Federico; Ferrucci, Roberta; Barbieri, Sergio; Ruggiero, Fabiana; Priori, Alberto; Silani, Vincenzo; Ticozzi, Nicola; Poletti, Barbara.
Afiliação
  • Aiello EN; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy, e.aiello@auxologico.it.
  • Solca F; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Torre S; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Colombo E; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Maranzano A; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • De Lorenzo A; Neurology Residency Program, Università Degli Studi di Milano, Milano, Italy.
  • Patisso V; Neurology Residency Program, Università Degli Studi di Milano, Milano, Italy.
  • Treddenti M; Neurology Residency Program, Università Degli Studi di Milano, Milano, Italy.
  • Curti B; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Morelli C; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Doretti A; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Verde F; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Ferrucci R; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università Degli Studi di Milano, Milano, Italy.
  • Barbieri S; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
  • Ruggiero F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Priori A; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Silani V; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Ticozzi N; Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milano, Italy.
  • Poletti B; ASST Santi Paolo e Carlo, San Paolo University Hospital, Milano, Italy.
Eur Neurol ; 87(2): 79-83, 2024.
Article em En | MEDLINE | ID: mdl-38643758
ABSTRACT

INTRODUCTION:

The present study aimed at testing the longitudinal feasibility of the Montreal Cognitive Assessment (MoCA) in an Italian cohort of non-demented amyotrophic lateral sclerosis (ALS) patients.

METHODS:

N = 39 non-demented ALS patients were followed-up at a 5-to-10-month interval (M = 6.8; SD = 1.4) with the MoCA and the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Practice effects, test-retest reliability, and predictive validity (against follow-up ECAS scores) were assessed. Reliable change indices (RCIs) were derived via a regression-based approach by accounting for retest interval and baseline confounders (i.e., demographics, disease duration, and severity and progression rate).

RESULTS:

At retest, 100% and 69.2% of patients completed the ECAS and the MoCA, respectively. Patients who could not complete the MoCA showed a slightly more severe and fast-progressing disease. The MoCA was not subject to practice effects (t[32] = -0.80; p = 0.429) and was reliable at retest (intra-class correlation = 0.82). Moreover, baseline MoCA scores predicted the ECAS at retest. RCIs were successfully derived - with baseline MoCA scores being the only significant predictor of retest performances (ps < 0.001).

CONCLUSIONS:

As long as motor disabilities do not undermine its applicability, the MoCA appears to be longitudinally feasible at a 5-to-10-month interval in non-demented ALS patients. However, ALS-specific screeners - such as the ECAS - should be preferred whenever possible.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estudos de Viabilidade / Testes de Estado Mental e Demência / Esclerose Lateral Amiotrófica Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Eur Neurol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estudos de Viabilidade / Testes de Estado Mental e Demência / Esclerose Lateral Amiotrófica Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Eur Neurol Ano de publicação: 2024 Tipo de documento: Article